NO20040405L - Farmasoytiske sammensetninger av amlodipin og atorvastatin. - Google Patents

Farmasoytiske sammensetninger av amlodipin og atorvastatin.

Info

Publication number
NO20040405L
NO20040405L NO20040405A NO20040405A NO20040405L NO 20040405 L NO20040405 L NO 20040405L NO 20040405 A NO20040405 A NO 20040405A NO 20040405 A NO20040405 A NO 20040405A NO 20040405 L NO20040405 L NO 20040405L
Authority
NO
Norway
Prior art keywords
amlodipine
atorvastatin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
NO20040405A
Other languages
English (en)
Inventor
Laman Alani
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20040405L publication Critical patent/NO20040405L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
NO20040405A 2001-07-31 2004-01-29 Farmasoytiske sammensetninger av amlodipin og atorvastatin. NO20040405L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30913301P 2001-07-31 2001-07-31
PCT/IB2002/002988 WO2003011283A1 (en) 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
NO20040405L true NO20040405L (no) 2004-03-08

Family

ID=23196829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040405A NO20040405L (no) 2001-07-31 2004-01-29 Farmasoytiske sammensetninger av amlodipin og atorvastatin.

Country Status (46)

Country Link
US (2) US20030114497A1 (no)
EP (2) EP1411923B1 (no)
JP (3) JP4020863B2 (no)
KR (2) KR100674762B1 (no)
CN (2) CN1617717A (no)
AP (1) AP1745A (no)
AR (1) AR034925A1 (no)
AT (1) ATE385793T1 (no)
AU (1) AU2002355680B2 (no)
BR (1) BR0211548A (no)
CA (1) CA2444554C (no)
CO (1) CO5540287A2 (no)
CR (1) CR7219A (no)
CY (1) CY1107245T1 (no)
DE (1) DE60225014T2 (no)
DK (1) DK1411923T3 (no)
DO (1) DOP2002000445A (no)
EA (1) EA006998B1 (no)
EC (1) ECSP044965A (no)
ES (1) ES2298381T3 (no)
GE (1) GEP20063926B (no)
GT (1) GT200200158A (no)
HN (1) HN2002000198A (no)
HR (1) HRP20040067A2 (no)
HU (1) HUP0401569A2 (no)
IL (1) IL159440A0 (no)
IS (1) IS7089A (no)
MA (1) MA27052A1 (no)
MX (1) MXPA04000270A (no)
MY (1) MY137519A (no)
NI (1) NI200200095A (no)
NO (1) NO20040405L (no)
NZ (1) NZ530247A (no)
OA (1) OA13300A (no)
PA (1) PA8551701A1 (no)
PE (1) PE20030324A1 (no)
PL (1) PL368519A1 (no)
PT (1) PT1411923E (no)
RS (1) RS5304A (no)
SG (1) SG143982A1 (no)
SV (1) SV2003001189A (no)
TN (1) TNSN04022A1 (no)
UA (1) UA79750C2 (no)
UY (1) UY27402A1 (no)
WO (1) WO2003011283A1 (no)
ZA (1) ZA200400659B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
MX2007000582A (es) * 2004-07-16 2007-03-30 Lek Pharmaceuticals Productos de degradacion oxidativa de atorvastatin calcio.
JP2007512357A (ja) * 2004-09-28 2007-05-17 テバ ファーマシューティカル インダストリーズ リミティド 不純物を実質的に含まないアトルバスタチンカルシウムの形態を調製するための方法
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
WO2006070248A1 (en) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
NZ561486A (en) * 2005-03-15 2011-03-31 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril
EP2000137B1 (en) 2006-03-29 2015-10-21 Kowa Company, Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
KR100793321B1 (ko) * 2006-11-29 2008-01-11 사회복지법인 삼성생명공익재단 후각장애 치료 및 예방용 조성물
CN101433539A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和他汀类药物的治疗组合物
EP2070520A1 (en) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
WO2009116061A2 (en) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Stable oral pharmaceutical composition comprising atorvastatin
DK2165702T3 (da) 2008-09-17 2012-03-05 Helm Ag Stabile og let opløselige sammensætninger af candesartancilexetil fremstillet ved vådgranulering
WO2010036600A1 (en) * 2008-09-24 2010-04-01 Merck Sharp & Dohme Corp. Pharmaceutical compositions of atorvastatin
EP2575757A1 (en) * 2010-06-03 2013-04-10 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
CN107028926A (zh) 2011-08-26 2017-08-11 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
US10350171B2 (en) * 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN109180701A (zh) * 2018-09-07 2019-01-11 中国药科大学 一种化合物2016a0c1药物组合物的共无定形物
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN111689922B (zh) * 2020-07-17 2022-03-15 江西施美药业股份有限公司 一种苯磺酸左旋氨氯地平环合杂质的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI1148049T1 (en) * 1995-07-17 2005-02-28 Warner-Lambert Company Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
EP0858336B1 (en) * 1995-11-02 2006-12-20 Warner-Lambert Company Llc Method and pharmaceutical composition for regulating lipid concentration
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
JP2001514224A (ja) * 1997-08-29 2001-09-11 ファイザー・プロダクツ・インク アムロジピンとスタチン化合物を含む併用療法
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
PL341397A1 (en) * 1997-11-25 2001-04-09 Warner Lambert Co Inhibition of lipoprotein oxidation
AP2001002324A0 (en) * 1999-04-23 2001-12-31 Preston Mason Synergistic effect of amlodipine atorvastatin.
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
AU2001283085A1 (en) * 2000-08-04 2002-02-18 R. Preston Mason Synergistic effect of amlodipine and atorvastatin

Also Published As

Publication number Publication date
AU2002355680B2 (en) 2007-11-15
IL159440A0 (en) 2004-06-01
DE60225014T2 (de) 2008-06-12
PL368519A1 (en) 2005-04-04
US20050107446A1 (en) 2005-05-19
DE60225014D1 (de) 2008-03-27
EA200400028A1 (ru) 2004-08-26
ECSP044965A (es) 2004-03-23
CR7219A (es) 2004-03-24
DOP2002000445A (es) 2003-01-31
CY1107245T1 (el) 2012-11-21
AR034925A1 (es) 2004-03-24
EA006998B1 (ru) 2006-06-30
GT200200158A (es) 2003-05-15
PE20030324A1 (es) 2003-04-03
JP2007153908A (ja) 2007-06-21
UA79750C2 (en) 2007-07-25
JP2005501051A (ja) 2005-01-13
NI200200095A (es) 2004-06-07
AP1745A (en) 2007-05-30
IS7089A (is) 2003-12-22
RS5304A (en) 2006-10-27
HUP0401569A2 (hu) 2004-12-28
PA8551701A1 (es) 2003-02-14
CN101185646A (zh) 2008-05-28
JP4020863B2 (ja) 2007-12-12
HRP20040067A2 (en) 2005-02-28
SG143982A1 (en) 2008-07-29
OA13300A (en) 2007-04-13
HN2002000198A (es) 2005-10-20
WO2003011283A1 (en) 2003-02-13
MXPA04000270A (es) 2004-05-04
UY27402A1 (es) 2003-02-28
ATE385793T1 (de) 2008-03-15
GEP20063926B (en) 2006-09-25
ES2298381T3 (es) 2008-05-16
KR20060054495A (ko) 2006-05-22
CO5540287A2 (es) 2005-07-29
MY137519A (en) 2009-02-27
EP1411923A1 (en) 2004-04-28
EP1852116A1 (en) 2007-11-07
SV2003001189A (es) 2003-03-18
NZ530247A (en) 2006-06-30
ZA200400659B (en) 2005-04-28
CA2444554A1 (en) 2003-02-13
KR20040032148A (ko) 2004-04-14
JP2007314566A (ja) 2007-12-06
MA27052A1 (fr) 2004-12-20
TNSN04022A1 (fr) 2006-06-01
CA2444554C (en) 2007-09-04
EP1411923B1 (en) 2008-02-13
US20030114497A1 (en) 2003-06-19
DK1411923T3 (da) 2009-01-05
AP2004002963A0 (en) 2004-03-31
BR0211548A (pt) 2004-07-13
KR100674762B1 (ko) 2007-01-25
CN1617717A (zh) 2005-05-18
PT1411923E (pt) 2008-04-02

Similar Documents

Publication Publication Date Title
NO20040405L (no) Farmasoytiske sammensetninger av amlodipin og atorvastatin.
DK200300344U1 (da) Amlodipinmaleat og farmaceutisk præparat indeholdende amlodipinmaleat
ATE332689T1 (de) Therapeutische zusammensetzungen, enthaltend amlodipin und atorvastatin
NO20031744L (no) Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
IS6304A (is) Kínasólínefnasambönd og lyfjafræðilegar efnasamsetningar sem innihalda þau
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
FI6787U1 (fi) Amlodipiinimaleaattia sisältävät farmaseuttiset koostumukset
IS7304A (is) Tvívetnissetin pýrasólýlbensýlsúlfónamíð og lyf sem innihalda téð efnasambönd
NO20041607L (no) Doseringsregime og farmasoytisk preparat for nodprevensjon
EE200100632A (et) Amlodipiini ja atorvastatiini ühine sool
NO20040390L (no) Krystallinske former VI og VII av atorvastatinkalsium.
IS2841B (is) Samstæða hluta og lyfjasamsetningar
NO20015756D0 (no) Felles promedikamenter av amlodipin og atorvastatin
NO20024354L (no) N-deacetyltiocolchicin-derivater og farmasöytiske sammensetninger inneholdende dem
NO20011703D0 (no) Kondensator av ikke-brennbar og uhellsforhindrende type
DK1385513T3 (da) Farmaceutiske kombinationer af pyridoindollonderivater og anticancermidler
NO20015128L (no) Synergistiske virkninger av amlodipin og atorvastatin
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
NO331169B1 (no) Krystallinsk form av et fenyletanolamin, fremstilling derav og farmasoytisk preparat og legemiddel omfattende den samme
NO20042126L (no) Syntese av 2-aralkoksyadenosiner og 2-alkoksyadenosiner
DK200100250U3 (da) Aspartatderivat af amlodipin og farmaceutiske præparater indeholdende dette.
DK200100256U3 (da) Amlodipinmaleat og farmaceutiske præparater indeholdende dette
DK200100249U3 (da) Amlodipinhemimaleat og farmaceutiske præparater indeholdende dette

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application